Patent US1608200A successfully refreshed from Google Patents.
Patent US4425345A successfully refreshed from Google Patents.
US4425345A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition containing triamterene
Assignee: Smith and Nephew PLC
•
Filing: 1981-12-08
•
Granted: 1984-01-10
•
Expires: 2001-12-08
Abstract
Abstract A sterile, non-irritant, non-toxic aqueous solution adapted for topical administration to the eye which contains 2,4,7-triamino-6-phenylpteridine rendered soluble by a solubilizing amount of a xanthine derivative. The composition may be used to treat ocular hypertension and glaucoma.
Inventors
- 👤 Michael Horlington
- 👤 Lindsey V. Scott
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 22:43
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K9/00; A61K9/0012; A61K9/0048
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
50 words
A method for reducing the intra-ocular pressure in the eye of a patient having glaucoma which comprises topically applying to the surface of the eye a sterile, aqueous solution comprising an effective intra-ocular pressure reducing amount of triamterene rendered soluble by an effective solubilizing amount of a water soluble xanthine.
Claim 2
Independent Claim
50 words
A method for reducing the intra-ocular pressure in the eye of a patient having glaucoma which comprises topically applying to the surface of the eye a sterile, aqueous solution comprising an effective intra-ocular pressure reducing amount of triamterene rendered soluble by an effective solubilizing amount of a water soluble xanthine.
Claim 3
Dependent Claim
18 words
A method according to claim 1 in which the aqueous solution contains from 0.05 to 0.4% of triamterene.
Claim 4
Dependent Claim
18 words
A method according to claim 1 in which the aqueous solution contains from 0.1 to 0.3% of triamterene.
Claim 5
Dependent Claim
19 words
A method according to claim 1 in which the aqueous solution contains from 0.1 to 10% of a xanthine.
Claim 6
Dependent Claim
19 words
A method according to claim 1 in which the aqueous solution contains from 1 to 8% of a xanthine.
Claim 7
Dependent Claim
12 words
A method according to claim 4 in which the xanthine is proxyphylline.
Claim 8
Dependent Claim
12 words
A method according to claim 4 in which the xanthine is dyphylline.
Claim 9
Dependent Claim
13 words
A method according to claim 4 in which the xanthine is hydroxyethyl theophylline.
Claim 10
Dependent Claim
15 words
A method according to claim 1 in which the aqueous solution is rendered substantially isotonic.
Claim 11
Dependent Claim
18 words
A method according to claim 1 in which the pH of the aqueous solution is 6.0 to 8.5.
Claim 12
Dependent Claim
18 words
A method according to claim 1 in which the aqueous solution contains an effective amount of a preservative.
Claim 13
Dependent Claim
15 words
A method according to claim 1 in which the preservative is a quaternary ammonium compound.
Claim 14
Dependent Claim
13 words
A method according to claim 12 in which the preservative is benzalkonium chloride.
Claim 15
Dependent Claim
19 words
A method according to claim 13 in which the aqueous solution contains from 0.005 to 0.04% of benzalkonium chloride.
Claim 16
Dependent Claim
25 words
A method according to claim 1 in which the aqueous solution contains a buffer to give the solution a pH of between 5.0 and 8.0.
Claim 17
Dependent Claim
31 words
A method according to claim 1 in which the aqueous solution contains an effective amount of a further solubilizing agent capable of increasing the amount of triamterene in the aqueous solution.
Claim 18
Dependent Claim
46 words
A sterile, aqueous solution for reducing the intra-ocular pressure in the eye of a patient having glaucoma adapted for topical application to the eye which comprises an effective intra-ocular pressure reducing amount of triamterene rendered soluble by an effective solubilizing amount of a water soluble xanthine.
Claim 19
Dependent Claim
46 words
A sterile, aqueous solution for reducing the intra-ocular pressure in the eye of a patient having glaucoma adapted for topical application to the eye which comprises an effective intra-ocular pressure reducing amount of triamterene rendered soluble by an effective solubilizing amount of a water soluble xanthine.
Claim 20
Dependent Claim
15 words
An aqueous solution according to claim 17 which contains from 0.05 to 0.4% of triamterene.
Claim 21
Dependent Claim
17 words
An aqueous solution according to claim 17 which contains from 0.1 to 10% of a water-soluble xanthine.
Claim 22
Dependent Claim
13 words
An aqueous solution according to claim 19 in which the xanthine is dyphylline.
Claim 23
Dependent Claim
13 words
An aqueous solution according to claim 19 in which the xanthine is proxyphylline.
Claim 24
Dependent Claim
14 words
An aqueous solution according to claim 19 in which the xanthine is hydroxyethyl theophylline.
Claim 25
Dependent Claim
16 words
An aqueous solution according to claim 17 in which the aqueous solution is rendered substantially isotonic.
Claim 26
Dependent Claim
19 words
An aqueous solution according to claim 17 in which the pH of the aqueous solution is 6.0 to 8.5.
Claim 27
Dependent Claim
15 words
An aqueous solution according to claim 17 which contains an effective amount of a preservative.
Claim 28
Dependent Claim
16 words
An aqueous solution according to claim 25 in which the preservative is a quaternary ammonium compound.
Claim 29
Dependent Claim
14 words
An aqueous solution according to claim 26 in which the preservative is benzalkonium chloride.
Claim 30
Dependent Claim
15 words
An aqueous solution according to claim 27 which contains from 0.005 to 0.04% benzalkonium chloride.
Claim 31
Dependent Claim
22 words
An aqueous solution according to claim 17 which contains a buffer to give the solution a pH of between 5.0 and 8.0.
Claim 32
Dependent Claim
28 words
An aqueous solution according to claim 17 which contains an effective amount of a further solubilizing agent capable of increasing the concentration of triamterene in the aqueous solution.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-01-09 | 1987-07-11 | 1988-01-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-01-09 | 1991-07-11 | 1992-01-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-01-09 | 1995-07-11 | 1996-01-10 | $7700.00 | Window Closed / Lapsed |